Advertisement Phosplatin starts dosing in Phase I trial of PT-112 for solid tumors - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Phosplatin starts dosing in Phase I trial of PT-112 for solid tumors

Phosplatin Therapeutics has dosed the first group of patients in its Phase I first-in-human clinical trial of PT-112, the lead therapeutic candidate among its phosphaplatin family of molecules, to treat solid tumors.

Around 80 patients will be enrolled in the trial across three sites including The University of Texas MD Anderson Cancer Center, the Sarah Cannon Research Institute and the University of Colorado Cancer Center.

The trial will include two parts, a dose escalation portion to evaluate the safety, pharmacokinetic behavior and maximum tolerated dose of PT-112 in an open label setting of solid tumor cancer patients.

The subsequent dose confirmation portion will consider the drug candidate’s activity in discreet group of patients with specific disease characteristics.

Phosplatin Therapeutics CEO Robert Fallon said: "For a small company like ours it is both encouraging, and testimony to the therapeutic potential of our compound, that we have been able to line up a top-tier group of clinical sites and investigators to lead the first trial of PT-112 in humans."

In pre-clinical studies, PT-112’s unique electrochemistry and plasma stability engendered improved tolerability and safety, and proved highly efficacious in several mouse models using patient-derived tumors when compared to prior members of the platinum therapeutic class.